Publications by authors named "A Zivi"
Epigenetic dysregulation has long been recognized as a significant contributor to tumorigenesis and tumor maintenance, impacting all recognized cancer hallmarks. Although some epigenetic drugs have received regulatory approval for certain hematological malignancies, their efficacy in treating solid tumors has so far been largely disappointing. However, recent advancements in developing new compounds and a deeper understanding of cancer biology have led to success in specific solid tumor subtypes through precision medicine approaches.
View Article and Find Full Text PDFArticle Synopsis
- Advanced urothelial carcinoma has limited treatment options, particularly in later stages, with only a few drugs showing clinical effectiveness.
- The article highlights a young patient with serious cardiovascular issues who has already been treated with first- and second-line therapies and has liver metastases.
- Despite the generally poor prognosis, the patient responded well to a third-line treatment involving gemcitabine, making this case noteworthy for its unique therapy approach and disease progression.
Background: Second- or third-line treatment options for metastatic renal cell carcinoma (mRCC) have dramatically changed in the last few years. There are no criteria for the choice between nivolumab and cabozantinib, which both demonstrated overall survival (OS) gain in pivotal trials.
Objective: We conducted an analysis of oncological outcomes in patients treated in the Veneto Region (Italy), studying different sequences of TKI-nivolumab-cabozantinib or TKI-cabozantinib-nivolumab in a publicly funded healthcare system.
Background: Thyroid hormone impairment, represented as an alteration in levels of thyroid hormones and a lower fT3/fT4 ratio, has been correlated with a worse prognosis for both cancer and non-cancer patients. The role of baseline thyroid function in patients with metastatic renal cell carcinoma (mRCC) however, has not been studied yet.
Materials And Methods: We recorded clinical data, baseline biochemical results, and oncological outcomes from 10 Oncology Units in Italy.